Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis.

Verma S, Liew A, Subramaniam M, Poon LY.

Aust N Z J Psychiatry. 2009 Sep;43(9):812-7. doi: 10.1080/00048670903107609.

PMID:
19670054
2.
3.

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A.

Aust N Z J Psychiatry. 2007 Dec;41(12):980-9.

PMID:
17999270
4.

Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial.

Alvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL, Pérez-Iglesias R, Martínez-García O, Pérez-Pardal T, Ramírez-Bonilla ML, Crespo-Facorro B.

J Clin Psychiatry. 2006 Aug;67(8):1253-60.

PMID:
16965204
5.
6.

Effects of second generation antipsychotics on leptin and ghrelin.

Esen-Danaci A, Sarandöl A, Taneli F, Yurtsever F, Ozlen N.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1434-8. doi: 10.1016/j.pnpbp.2008.03.015. Epub 2008 Apr 1.

PMID:
18579280
7.

Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment.

Maayan LA, Vakhrusheva J.

Hum Psychopharmacol. 2010 Mar;25(2):133-8. doi: 10.1002/hup.1097.

PMID:
20196182
8.

No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.

Zhang ZJ, Yao ZJ, Zhang XB, Chen JF, Sun J, Yao H, Hou G, Zhang XB.

Acta Pharmacol Sin. 2003 Mar;24(3):235-40.

9.

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal.

Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, Hetrick S, Rodríguez-Sánchez JM, Pérez-Iglesias R, Vázquez-Barquero JL.

CNS Drugs. 2008;22(7):547-62. Review.

PMID:
18547125
10.

Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review.

Koponen H, Saari K, Savolainen M, Isohanni M.

Eur Arch Psychiatry Clin Neurosci. 2002 Dec;252(6):294-8. Review.

PMID:
12563538
11.

Effects of an educational intervention on weight gain in patients treated with antipsychotics.

Mauri M, Castrogiovanni S, Simoncini M, Iovieno N, Miniati M, Rossi A, Dell'Agnello G, Fagiolini A, Donda P, Cassano GB.

J Clin Psychopharmacol. 2006 Oct;26(5):462-6.

PMID:
16974185
12.

Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics.

Leitão-Azevedo CL, Guimarães LR, de Abreu MG, Gama CS, Lobato MI, Belmonte-de-Abreu PS.

Rev Bras Psiquiatr. 2006 Dec;28(4):301-4.

13.

Metabolic risk factors in drug-naive patients with first-episode psychosis.

Verma SK, Subramaniam M, Liew A, Poon LY.

J Clin Psychiatry. 2009 Jul;70(7):997-1000. doi: 10.4088/JCP.08m04508. Epub 2009 Jun 2.

PMID:
19497246
14.

Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis.

Thompson A, Hetrick SE, Alvarez-Jiménez M, Parker AG, Willet M, Hughes F, Gariup M, Gomez DL, McGorry PD.

Aust N Z J Psychiatry. 2011 Sep;45(9):740-8. doi: 10.3109/00048674.2011.595370. Epub 2011 Aug 10.

PMID:
21827345
15.
16.
17.

Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.

Chen CK, Chen YC, Huang YS.

Psychiatry Clin Neurosci. 2009 Feb;63(1):17-22. doi: 10.1111/j.1440-1819.2008.01886.x. Epub 2008 Dec 1.

18.

Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study.

Curtis J, Henry C, Watkins A, Newall H, Samaras K, Ward PB.

Early Interv Psychiatry. 2011 May;5(2):108-14. doi: 10.1111/j.1751-7893.2011.00262.x. Epub 2011 Apr 7.

PMID:
21470374
19.

Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.

Pérez-Iglesias R, Martínez-García O, Pardo-Garcia G, Amado JA, Garcia-Unzueta MT, Tabares-Seisdedos R, Crespo-Facorro B.

Int J Neuropsychopharmacol. 2014 Jan;17(1):41-51. doi: 10.1017/S1461145713001053. Epub 2013 Oct 8.

PMID:
24103107
20.

Naturalistic impact of second-generation antipsychotics on weight gain.

Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, Oderda GM.

Ann Pharmacother. 2006 Apr;40(4):626-32. Epub 2006 Mar 28.

PMID:
16569802

Supplemental Content

Support Center